Pearl Samson
Overview
Explore the profile of Pearl Samson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaur A, Capparelli E, Calabrese K, Baltrusaitis K, Marzinke M, McCoig C, et al.
Lancet HIV
. 2024 Mar;
11(4):e211-e221.
PMID: 38538160
Background: Combined intramuscular long-acting cabotegravir and long-acting rilpivirine constitute the first long-acting combination antiretroviral therapy (ART) regimen approved for adults with HIV. The goal of the IMPAACT 2017 study (MOCHA...
2.
Bekker A, Capparelli E, Violari A, Cotton M, Cababasay M, Wang J, et al.
Lancet HIV
. 2021 Dec;
9(1):e24-e31.
PMID: 34883066
Background: No evidence-based optimal dosing guidance is available for abacavir liquid formulation use from birth. We used abacavir pharmacokinetic data from neonates and infants to determine an exact abacavir dosing...
3.
Nikanjam M, Tran L, Chadwick E, Bwakura-Dangarembizi M, Moore C, Samson P, et al.
AIDS
. 2021 Dec;
36(4):525-532.
PMID: 34873089
Objective: Dosing efavirenz (EFV) in children less than 3 years of age is challenging due to large variability in drug levels. This study evaluated differences in pharmacokinetics with tuberculosis (TB)...
4.
Rosebush J, Best B, Chadwick E, Butler K, Moye J, Smith E, et al.
AIDS
. 2020 Nov;
35(3):419-427.
PMID: 33252481
Objective: The aim of this study was to evaluate safety and pharmacokinetics of maraviroc administered with standard antiretroviral prophylaxis to HIV-1 exposed infants and to determine the appropriate dose of...
5.
Krogstad P, Samson P, Acosta E, Moye J, Townley E, Bradford S, et al.
J Pediatric Infect Dis Soc
. 2020 May;
10(2):201-204.
PMID: 32448902
Clinical Trials Registration: NCT01751568.
6.
Meyers T, Samson P, Acosta E, Moye J, Townley E, Bradford S, et al.
AIDS
. 2019 Nov;
33(14):2197-2203.
PMID: 31689263
Objectives: Drug-drug interactions limit current antiretroviral treatment options for HIV-infected children with tuberculosis (TB). Rifampicin (RIF) induces UDP-glucuronosyltransferase activity, accelerating the clearance of raltegravir (RAL). We sought to establish an...
7.
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years
Bwakura Dangarembizi M, Samson P, Capparelli E, Moore C, Jean-Philippe P, Spector S, et al.
J Acquir Immune Defic Syndr
. 2019 Jun;
81(4):473-480.
PMID: 31241542
Background: CYP2B6 516 genotype-directed dosing improves efavirenz (EFV) exposures in HIV-infected children younger than 36 months, but such data are lacking in those with tuberculosis (TB) coinfection. Methods: Phase I,...
8.
Higa N, Pelz A, Birch D, Beck I, Sils T, Samson P, et al.
J Pediatric Infect Dis Soc
. 2019 Jun;
9(2):261-264.
PMID: 31194860
Among 66 antiretroviral-naive children aged <3 years with human immunodeficiency virus (HIV) or coinfected with HIV and tuberculosis and initiating efavirenz-based antiretroviral therapy (ART), non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance...
9.
Moore C, Capparelli E, Samson P, Bwakura-Dangarembizi M, Jean-Philippe P, Worrell C, et al.
AIDS
. 2017 Mar;
31(8):1129-1136.
PMID: 28323755
Objectives: To determine safety-specific, efficacy-specific and genotypic-specific dose requirements of efavirenz (EFV) in children aged 3 to less than 36 months with HIV infection. Design: IMPAACT P1070 was a 24-week...
10.
Nachman S, Ahmed A, Amanullah F, Becerra M, Botgros R, Brigden G, et al.
Lancet Infect Dis
. 2015 May;
15(6):711-20.
PMID: 25957923
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective, are hampered by high...